Drug resistance and use of long-acting ART-Reference-Cited by-同舟云学术

Drug resistance and use of long-acting ART

Published:2022-06 Issue:6 Volume:9 Page:e374-e375
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

da Silva Juliana,Siedner Mark,McCluskey Suzanne,Chandiwana Nomathemba,Venter Francois,Raizes Elliot

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference8 articles.

1. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis;Cutrell;AIDS,2021

2. The challenge of HIV-1 subtype diversity;Taylor;N Engl J Med,2008

3. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection;Orkin;N Engl J Med,2020

4. Resistance testing for management of HIV virologic failure in sub-Saharan Africa: an unblinded randomized controlled trial;Siedner;Ann Intern Med,2021

5. Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa;Reynolds;HIV Med,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022;Journal of Antimicrobial Chemotherapy;2024-07-24

2. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens;Open Forum Infectious Diseases;2024-01-24

3. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use;Journal of Antimicrobial Chemotherapy;2023-08-16

4. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries;AIDS;2023-02-04

5. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs);Clinical Infectious Diseases;2022-11-21